PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8734306-1	1996	OBJECTIVES AND METHODS: The purpose of this study was to compare the effects of peptide YY (PYY) and neuropeptide Y (NPY) on VIP- and PGE2-stimulated intestinal net water flux at three different levels of the small intestine (duodenum, jejunum, ileum), by a technique of in situ closed loops in anaesthetised rats.	Dinoprostone	134-138	neuropeptide Y	Rattus norvegicus	101-115	
17143304-0	2007	Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors.	Dinoprostone	51-67	neuropeptide Y	Rattus norvegicus	0-14	
17143304-6	2007	Pretreatment with the Y1 agonist [Leu31,Pro34]-NPY, inhibited BK/PGE2-evoked CGRP release.	Dinoprostone	65-69	neuropeptide Y	Rattus norvegicus	47-50	
17143304-9	2007	Similarly, [Leu31,Pro34]-NPY inhibited BK/PGE2-evoked increases in intracellular calcium levels whereas PYY(3-36) increased responses.	Dinoprostone	42-46	neuropeptide Y	Rattus norvegicus	25-28	
17143304-10	2007	NPY inhibition of BK/PGE2-evoked release of CGRP was reversed by the Y1 receptor antagonist, BIBO3304, and higher concentrations of BIBO3304 significantly facilitated CGRP release.	Dinoprostone	21-25	neuropeptide Y	Rattus norvegicus	0-3	
14511074-8	2003	The prostaglandin (PG) analogue PGE2 attenuated the evoked increase in NPY-ir overflow as well as a modest decrease in NA.	Dinoprostone	32-36	neuropeptide Y	Rattus norvegicus	71-74	
8734306-3	1996	PGE2-stimulated net water flux was also efficiently inhibited in the jejunum and ileum; PYY (ID50 about 10 pmol/kg.h) was 30 to 90 fold more potent than NPY.	Dinoprostone	0-4	neuropeptide Y	Rattus norvegicus	153-156	
8734306-1	1996	OBJECTIVES AND METHODS: The purpose of this study was to compare the effects of peptide YY (PYY) and neuropeptide Y (NPY) on VIP- and PGE2-stimulated intestinal net water flux at three different levels of the small intestine (duodenum, jejunum, ileum), by a technique of in situ closed loops in anaesthetised rats.	Dinoprostone	134-138	neuropeptide Y	Rattus norvegicus	117-120	
2464161-4	1988	Data presented here shows that NPY responsiveness is restored, in piroxicam pretreated tissues, by vasoactive intestinal polypeptide (VIP), forskolin, prostaglandin E2 (PGE2) isobutyl-1-methyl-xanthine (IBMX) and dibutyryl cAMP added prior to the neuropeptide.	Dinoprostone	151-167	neuropeptide Y	Rattus norvegicus	31-34	
7582505-10	1995	This inhibition could be overcome by restoring basal Isc with prostaglandin E2, indicating that the effect of NPY is not mediated by nerves or prostaglandins, but that NPY is only effective, when anion secretion is stimulated by the spontaneous release of neurotransmitters and prostaglandins.	Dinoprostone	62-78	neuropeptide Y	Rattus norvegicus	110-113	
7582505-12	1995	NPY inhibited the increase in Isc induced by veratridine and prostaglandin E2, but it had no effect on the Isc induced by direct stimulation of the adenylate cyclase with forskolin, or on Isc induced by stimulation of the Ca(2+)-pathway with carbachol.	Dinoprostone	61-77	neuropeptide Y	Rattus norvegicus	0-3	
7582505-13	1995	Inhibition of the response to veratridine or prostaglandin E2 by NPY showed the same dependence on the height of the ISC just prior to addition of NPY as seen in control conditions, i.e. NPY inhibited 55% of cyclic AMP-mediated secretion.6.	Dinoprostone	45-61	neuropeptide Y	Rattus norvegicus	65-68	
2464161-4	1988	Data presented here shows that NPY responsiveness is restored, in piroxicam pretreated tissues, by vasoactive intestinal polypeptide (VIP), forskolin, prostaglandin E2 (PGE2) isobutyl-1-methyl-xanthine (IBMX) and dibutyryl cAMP added prior to the neuropeptide.	Dinoprostone	169-173	neuropeptide Y	Rattus norvegicus	31-34	
3404443-2	1988	Administration of NPY (0.23-2.3 nmol) into the kidney produced a dose-related renal vasoconstriction and an increase in the output of PGE2 and 6-keto-PGF1 alpha, the stable hydrolysis product of PGI2.	Dinoprostone	134-138	neuropeptide Y	Rattus norvegicus	18-21	
29482802-10	2018	Hence, interaction with COX-2, NPY may affect the levels of PGF2alpha and PGE2 as well as impact the proliferation of granulosa cells in ovaries, thus further reducing the luteal formation, and promoting luteal structural and functional regression, as well as the ovarian steroidogenesis following EA treatment.	Dinoprostone	74-78	neuropeptide Y	Rattus norvegicus	31-34	
3552624-0	1987	Neuropeptide Y levels in microdissected regions of the hypothalamus and in vitro release in response to KCl and prostaglandin E2: effects of castration.	Dinoprostone	112-128	neuropeptide Y	Rattus norvegicus	0-14	
3866691-0	1985	Neuropeptide Y (NPY) and peptide YY (PYY) inhibit prostaglandin E2-induced intestinal fluid and electrolyte secretion in the rat jejunum in vivo.	Dinoprostone	50-66	neuropeptide Y	Rattus norvegicus	0-20	
3866691-5	1985	infusion of NPY significantly inhibited the effect of PGE2 (45 pmol X min-1) on fluid transport at infusion rates of 0.4 and 4.0 pmol X min-1 (P less than 0.01).	Dinoprostone	54-58	neuropeptide Y	Rattus norvegicus	12-15	
3866691-7	1985	PGE2-induced sodium and chloride secretion were also significantly reduced by NPY at an infusion rate of 0.4 but not of 0.04 pmol X min-1.	Dinoprostone	0-4	neuropeptide Y	Rattus norvegicus	78-81